Načítá se...
Hemophilia gene therapy comes of age
Concurrent with the development of recombinant factor replacement products, the characterization of the F9 and F8 genes over 3 decades ago allowed for the development of recombinant factor products and made the hemophilias a target disease for gene transfer. The progress of hemophilia gene therapy h...
Uloženo v:
| Vydáno v: | Blood Adv |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728634/ https://ncbi.nlm.nih.gov/pubmed/29296912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009878 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|